Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 3/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26830858 | 0.88 | HTT (0.36) | TSHRPOLBPTAFR | |
| SCHEMBL30194045 | 0.82 | CHRM1 (0.35) | TSHRALDH1A1POLBKMO | |
| SCHEMBL25359353 | 0.82 | CHRM1 (0.35) | TSHRALDH1A1POLBKMO | |
| SCHEMBL30193990 | 0.80 | CHRM1 (0.34) | TSHRPOLBKMO | |
| SCHEMBL25360668 | 0.80 | CHRM1 (0.34) | TSHRPOLBKMO | |
| SCHEMBL30193991 | 0.80 | CHRM1 (0.34) | TSHRPOLBKMO | |
| SCHEMBL26001241 | 0.79 | DRD2 (0.37) | TSHRPIK3CGPTAFRKMO | |
| SCHEMBL16063458 | 0.79 | EGFR (0.34) | TSHRALDH1A1POLBKMO | |
| SCHEMBL16063579 | 0.78 | EGFR (0.35) | ALDH1A1KMO | |
| SCHEMBL6911403 | 0.78 | SLC5A1 (0.33) | SLC5A1SLC5A2PTAFRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382876-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11827610-B2 | Protoporphyrinogen oxidase inhibitors | ENKO CHEM, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230265060-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827610-B2 | Protoporphyrinogen oxidase inhibitors | PPOX, PPIF, CYP4X1 | SLC5A1 3090/4885SLC5A2 3203/4885TSHR 3537/4885 |
| US-20230265060-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | PPOX, PPIF, CYP4X1 | SLC5A1 3070/4885SLC5A2 3155/4885TSHR 3531/4885 |
| US-20230382876-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | PPOX, PPIF, CYP4X1 | SLC5A1 3090/4885SLC5A2 3203/4885TSHR 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.